Bristol-Myers Squibb Co. (NYSE: BMY) will not pursue accelerated approval for its lung cancer treatment Opdivo sending the stock price plummeting $6.26 to close at $49.23.
Bristol-Myers will not pursue accelerated approval
January 20, 2017 at 16:17 PM EST